Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: February 2015

Chapter 5 - Fluid therapy in ICU

from Section 1 - Basic principles

References

1. ChowdhuryAH, CoxEF, FrancisST, LoboDN. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte® 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg 2012; 256 : 18–24.
2. LoboDN, StanaZ, SimpsonJAet al. Dilution and redistribution effects of rapid 2-litre infusions of 0.9% (w/v) saline and 5% (w/v) dextrose on haematological parameters and serum biochemistry in normal subjects: a double-blind crossover study. Clin Sci 2001; 101 : 173–9.
3. LoboDN, StangaZ, AloysiusMMet al. Effects of volume loading with 1 liter intravenous infusions of 0.9% saline, 4% succinylated gelatine (Gelofusine) and 6% hydroxyethyl starch (Voluven) on blood volume and endocrine responses: a randomized, three-way crossover study in healthy volunteers. Crit Care Med 2010; 38 : 464–70.
4. ReidF, LoboDN, WilliamsRNet al. (Ab)normal saline and physiological Hartmann’s solution: a randomized double-blind crossover study. Clin Sci 2003; 104 : 17–24.
5. BrunkhorstFM, EngelC, BloosF, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358 : 125–39.
6. PernerA, HaaseN, GuttormsenAB, et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 2012; 367 : 124–34.
7. MyburghJA, FinferS, BellomoR, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367 : 1901–11.
8. FinferS, BellomoR, BoyceNet al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350 : 2247–56.
9. VerheijJ, van LingenA, BeishuizenAet al. Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery. Intensive Care Med 2006; 32 : 1030–8.
10. van der HeijdenM, VerheijJ, van Nieuw AmerongenGP, GroeneveldAB. Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia. Crit Care Med 2009; 37 : 1275–81.
11. LevickJF, MichelCC. Microvascular fluid exchange and the revised Starling principle. Cardiovasc Res 2010; 87 : 198–210.
12. GoldenbergNM, SteinbergBE, SlutskyAS, LeeWL. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med 2011; 3(88) : ps25.
13. MyburghJA, MythenMG. Resuscitation fluids. N Engl J Med 2013; 369 : 1243–51.
14. ZarychanskiR, Abou-SettaAM, TurgeonAF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013; 309 : 678–88.
15. HaaseN, PernerA, HenningsLI, et al. Hydroxyethyl starch 130/0.38–0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. Br Med J 2013; 346 : f839.
16. HartogC, ReinhartK. CONTRA: Hydroxeythyl starch solutions are unsafe in critically ill patients. Intensive Care Med 2009; 25 : 1337–42.
17. YunosNM, BellomoR, HegartyCet al. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012; 308 : 1566–72.
18. McCluskeySAet al. Hyperchloremia after noncardiac surgery is independently associated with increased morbidity and mortality: a propensity-matched cohort study. Anesth Analg 2013; 117 : 412–21.
19. WilkesNJ, WoolfR, MutchM, MallettSVet al. The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. Anesth Analg 2001; 93 : 811–6.
20. GuidetB, MartinetO, BoulainTet al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care 2012; 16 : R94.
21. Powell-TuckJ, GoslingP, LoboDNet al. British consensus guidelines on intravenous fluid therapy for adult surgical Patients, GIFTASUP. Available at http://www.bapen.org.uk/pdfs/bapen_pubs/giftasup.pdf (accessed June 2014).
22. TakilA, EtiZ, IrmakP, Yilmaz GogusF. Early postoperative respiratory acidosis after large intravascular volume infusion of lactated ringer’s solution during major spine surgery. Anesth Analg 2002; 95 : 294–8.
23. BurdettE, DushianthanA, Bennett-GuerreroEet al. Perioperative buffered versus non-buffered fluid administration for surgery in adults. Cochrane Database Syst Rev 2012; 12 : CD004089.
24. HartogCS, et al. Fluid replacement with hydroxyethyl starch in critical care – a reassessment. Dtsch Arztebl Int 2013;110:443–50.
25. BorkK. Pruritis precipitated by hydroxyethyll starch: a review. Br J Dermatol 2005; 152 : 3–12.
26. PatelA, WaheedU, BrettSJ. Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med 2013; 39 : 811–22.
27. GattasDJ, DanA, MyburghJet al. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 2013; 39 : 558–68.
28. GilliesMA, HabicherM, JhanjiSet al. Incidence of post-operative death and acute kidney injury associated with intravenous 6% hydroxyethyl starch use: systematic review and meta-analysis. Br J Anaesth 2014; 112 : 25–34.
29. BunnF, TrivediD. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 2012; 7 : CD001319.
30. PerelP, RobertsI, KerK. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013; 2 : CD000567.
31. DellingerRP, LevyMM, RhodesA, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41 : 580–637.
32. National Institute for Health and Care Excellence. Intravenous fluid therapy: Intravenous fluid therapy in adults in hospital. Clinical Guideline: Methods, evidence and recommendations, May 14, 2013. Available at http://www.nice.org.uk/nicemedia/live/13298/63879/63879.pdf (accessed June 2014).
33. AllisonSP, Lobo Dn. Debate: albumin administration should not be avoided. Crit Care 2000; 4 : 147–50.
34. RobertsI, BlackhallK, AldersonPet al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2011; 11 : CD001208.
35. MyburghJ, CooperDJ, FinferS, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357 : 874–84.
36. MullerRG, HaaseN, WetterslevJ, Perner. Effects of hydroxyethylstarch in subgroups of patients with severe sepsis: exploratory post-hoc analyses of a randomised trial. Intensive Care Med. 2013; 39 : 1963–71.
37. Medicines and US Food and Drugs Agency. FDA Safety Communication: Boxed Warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings, June 24, 2013. Available from http://www.fda.gov/biologicsbloodvaccines/safetyavailability/ucm358271.htm (accessed June 2014).
38. Government of Canada, Health Protection Branch. Voluven and Volulyte (hydroxyethyl starch (HES)) – Increased Mortality and Severe Renal Injury – Notice to Hospitals. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/34697a-eng.php (accessed June 2014).
39. Pharmacovigilance Risk Assessment Committee of the European Medicines Agency. PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144446.pdf (accessed July 2013).
40. Medicines and Health Care Healthcare Products Regulatory Agency. Class 2 drug alert (action within 48 hours): hydroxyethyl starch (HES) products—B Braun Melsungen AG and Fresenius Kabi Limited (EL (13)A/18). Available from http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON287025 (accessed July 2013).
41. BoydJH, ForbesJ, NakadaTet al. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011; 29 : 259–65.
42. DohertyM, BuggyDJ. Intraoperative fluids: how much is too much?Br J Anaesthesia 2012; 109 : 69–79.
43. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; WiedemannHP, WheelerAP, BernardGR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354 : 2564–75.